New data for KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)
X
A First-in-Class Investigational Bispecific Intravitreal Biologic for the Treatment of Macular Edema Secondary to Inflammation (MESI)
